(c) 2024 PillSync.com

zolpidem tartrate 12.5 mg

1 INDICATIONS AND USAGE Zolpidem tartrate extended-release tablets are indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance (as measured by wake time after sleep onset). The clinical trials performed in support of efficacy were up to 3 weeks (using polysomnography measurement up to 2 weeks in both adult and elderly patients) and 24 weeks (using patient-reported assessment in adult patients only) in duration [see Clinical Studies (14) ]. Zolpidem tartrate extended-release tablets, a gamma-aminobutyric acid (GABA) A receptor positive modulator, is indicated for the short-term treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance. ( 1 )

breckenridge pharmaceutical, inc.


11 months ago ROUND BLUE Z zolpidem tartrate 12.5 mg

ROUND BLUE Z

11 months ago ROUND BLUE Z zolpidem tartrate 12.5 mg

Z ROUND BLUE

16 HOW SUPPLIED/STORAGE AND HANDLING

ZOLPIDEM TARTRATE extended-release tablets, USP 6.25 mg are composed of two layers Layers are covered by the coating and are indistinguishable. and are pink, round, coated tablets debossed with "T" one side and plain on other side and supplied as: NDC Number Size 51991-981-01 bottle of 100

ZOLPIDEM TARTRATE extended-release tablets, USP 12.5 mg are composed of two layers and are blue, round, coated tablets debossed with "Z" one side and plain on other side and supplied as: NDC Number Size 51991-982-01 bottle of 100 Store between 15°C–25°C (59°F–77°F). Limited excursions permissible up to 30°C (86°F).


More pills like ROUND Z












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site